Eigen Therapeutics

We help targeted therapies hit their mark.

[Eigen Therapeutics @EigenTx]

Our priming platform extends beyond HER3: we're actively advancing programs including Nectin-4 & CD123, with ongoing screens for PSMA, GRPR, and other key ADC/RLT targets.

Stop by and discuss how priming therapies can overcome tumor heterogeneity and reshape oncology treatment!

[Eigen Therapeutics @EigenTx]

📅 Join us at #AACR25 on Sun, Apr 27, 2-5 PM, Section 16, Board 5 (Poster #338) for an in-depth look at how our priming platform expands the patient population & improves efficacy of ADCs and RLTs via selective antigen upregulation to tackle heterogeneity! https://t.co/nDzTyuMzkj

[Eigen Therapeutics @EigenTx]

This poster details our HER3 program: showcasing how we identify molecules that selectively upregulate HER3, aiming to improve treatment durability & expand the patient population for HER3-directed therapies. CTO @Kamran_Allele & CSO Kathryn Vanderlaag will be attending.

[Vibe Bio @VibeBio]

This #RareDiseaseWeek, we’re proud to celebrate our friends at @eigenTx + their work revolutionizing #cancertreatments. Their innovative platform is enhancing targeted therapies, offering new hope for rare disease patients. Learn about their work here:
https://t.co/TVAhRtFZ9u

[Eigen Therapeutics @EigenTx]

This research paves the way for not just increased durability of patient responses, but also broadens the potential patient base benefiting from antigen-directed therapies.

Stop by during #AACR2024 to see how we're pushing boundaries and shaping the future of cancer treatment.

[Eigen Therapeutics @EigenTx]

📅 Join us at #AACR2024 on April 9, 9:00 AM - 12:30 PM, Poster Section 42, Board #14 (Abstract #5092) for an in-depth look at how our priming platform expands the therapeutic window of antigen-directed therapies (ADCs, RLTs) through antigen modulation! https://t.co/9cqLaEyW46

[Eigen Therapeutics @EigenTx]

Antigens that we’ve utilized our platform on include CD123, HER2, HER3, TROP2, CD33, CD19, and CD22 (with more to come this year!).

[Eigen Therapeutics @EigenTx]

Eigen's CSO Kathryn, Senior Scientist Anu, and CTO Kamran are at #ASH2022! If you'd like to hear more about priming therapies, reach out to @Kamran_Allele (his DMs are open) or fill out the form at the bottom of https://t.co/Gs2BaCJXs5.

[Eigen Therapeutics @EigenTx]

At Eigen, we’re tackling tumor heterogeneity by utilizing our platform to design combination therapies. Click here to learn more about our mission and team.

https://t.co/RVmswxXbaS

[Eigen Therapeutics @EigenTx]

A huge thank you to @joshk and the @firstround team, @BuildersVC, @dropalltables, @MDe_Silva, @biovergehq, and many others. Your support and guidance have been key in helping us get here—and we’re just getting started!

https://t.co/iBzvAMttF3

[Eigen Therapeutics @EigenTx]

Targeted therapies are incredibly effective in some instances but can fail in others because cancer is heterogeneous. So we asked ourselves: what if we made cancer cells easier for targeted therapies to eliminate?

https://t.co/iBzvAMttF3

[Eigen Therapeutics @EigenTx]

Today we’re excited to announce our official launch! A big thank you to @KatherineMLewin and the great folks at @endpts for sharing our story.

https://t.co/rojBYDgquT